GLP-1 Demographics Statistics 2026

Who gets GLP-1?

In KFF's Health Tracking Poll fielded Oct 27–Nov 2, 2025, 18% of U.S. adults said they had ever taken a GLP-1 drug (for weight loss or a chronic condition) and 12% (about 1 in 8) said they were currently taking one, up 6 percentage points from May 2024. [1]

In KFF's May 2024 poll (fielded Apr 23–May 1, 2024), 12% of U.S. adults said they had ever taken a GLP-1 drug, including 6% who were currently taking one. [2]

Among U.S. adults who had ever used a GLP-1 (KFF, Oct–Nov 2025), 30% said they took it primarily to lose weight, 38% primarily to treat a chronic condition such as diabetes or heart disease, and 32% for both; overall 5% of all U.S. adults have taken a GLP-1 primarily to lose weight. [1]

KFF (Oct–Nov 2025): current GLP-1 use was highest among adults 50–64 (22%), versus 4% at ages 18–29, 11% at 30–49 and 9% at 65+; women were more likely than men to be current users (15% vs 9%). [1]

KFF (Oct–Nov 2025): current GLP-1 use was 45% among adults ever diagnosed with diabetes, 29% among those with heart disease, and 23% among those told they were overweight or obese in the past five years; insured adults were far more likely to be current users than uninsured adults (12% vs 4%). [1]

Where people get GLP-1s (KFF, Oct–Nov 2025): among adults who have ever taken one, 76% got it from their primary care doctor or a specialist, 17% from an online provider or website, and 9% from a medical spa or aesthetic medical center. [1]

In KFF's May 2024 poll, 79% of adults who had taken a GLP-1 got it (or the prescription) from their primary care doctor or a specialist, 11% from an online provider or website, and 10% from a medical spa or aesthetic medical center. [2]

Gallup's 2026 National Health and Well-Being Index survey (May 28–June 5, 2026; n=5,065) found 11% of U.S. adults currently take a GLP-1 medication for weight loss, up from 3% in 2024, and 15% have ever used one for weight loss. [3]

Gallup (2026 survey, n=5,065): among current GLP-1 weight-loss users, 66% use a brand-name product such as Ozempic or Wegovy, 18% use a compounded or 'custom-mixed' version, and 13% are unsure which they use. [3]

Gallup (2025, n=16,946, first three quarters of 2025) reported 12.4% of U.S. adults taking a GLP-1 specifically for weight loss (15.2% of women, 9.7% of men), up from 5.8% in February 2024; use was 16.2% at ages 40–49, 17.0% at 50–64 and 11.1% at 65+. [4]

What published research says

These numbers come from outside sources, not our directory; each one links to its source below.

• CDC/NCHS (NHANES, measured height and weight, August 2021–August 2023): 40.3% of U.S. adults had obesity and 9.4% had severe obesity; obesity was highest at ages 40–59 (46.4%). [5]
• In ASPS's 2025 member survey, 82% of ASPS member plastic surgeons reported consultation requests related to GLP-1 medication use; surgeons most often cited tummy tucks (88%), breast surgery (87%), arm lifts (84%) and facelifts (71%) in GLP-1-related consultations. [6]

What these numbers can't tell you

• Counts are Google Maps listings we classify as med spas, so they include dermatology and plastic surgery practices that offer med spa treatments and exclude spas without a Google listing.
• A treatment counts when the spa's Google listing or website names it, so a spa with an outdated menu can be over- or under-counted.
• We hold no patient records: every figure describes providers, their listings and their Google reviews, not who gets treated.

Medical disclaimer. MedSpaStandard is for education only and is not medical advice. Talk to a licensed provider about your own health, and check any provider's license with your state board.